Compare Gilead Sciences, Inc. (GILD) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Twilio Inc — how do they compare? Gilead Sciences, Inc. trades at $133.43 (market cap $163.51B), while Twilio Inc trades at $211.86 (market cap $32.11B). The key difference: Gilead Sciences, Inc. is far larger — about 5.1× Twilio Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| GILD | TWLO | |
|---|---|---|
Market Cap | $163.51B | $32.11B |
Sector | Health | Technology |
52-Week High | $155.80 | $236.64 |
52-Week Low | $108.22 | $92.44 |
Enterprise Value | $178.05B | $30.83B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Twilio (TWLO) trades at $217.83, showing modest daily weakness (-0.19%) but maintaining strong momentum with three consecutive earnings beats. The stock exhibits bullish technical signals with positive moving averages and strong institutional support. Recent financials show a significant turnaround with revenue reaching $5.07B in 2025 and net income turning positive at $33.83M, marking the company's first profitable year after previous losses. CEO Khozema Shipchandler's turnaround strategy and AI integration are driving renewed investor confidence.
Twilio presents a compelling turnaround story with improving fundamentals and strong analyst support (76.9% buy ratings), though elevated valuations (P/E 320.52) warrant caution. The company's AI-powered communication platform growth and margin expansion potential support upside to the $215.14 consensus target. Key risks include competitive pressures in customer engagement software and the need to sustain recent profitability gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
